Therapy Areas: Oncology
JW Therapeutics Secures USD 90m Financing to Develop Cell-based Therapy Technologies
12 March 2018 - - Shanghai-based clinical stage biopharmaceutical company JW Therapeutics has completed a USD 90m series A financing, where a consortium led by leading global investors Temasek, Sequoia Capital China, and YuanMing Capital is joined by a lineup of other investors, including Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group, and Juno Therapeutics, the company said.
JW Therapeutics was founded by Juno Therapeutics and WuXi AppTec Group in 2016.
By combining Juno's technology and platform with WuXi AppTec Group's local expertise, R and D and manufacturing platform, and broader partnerships, JW Therapeutics has successfully initiated the development of its first CD19-directed investigational therapy, JWCAR029 (a CAR-T therapy being studied for the treatment of B-cell malignancies initially focusing on relapsed and refractory DCBCL).
WuXi AppTec Group is a global pharmaceutical, medical device open-access capability and technology platform company with global operations.
The group provides a broad and integrated portfolio of services to help worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R and D through cost-effective and efficient solutions.
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Juno Therapeutics is a Celgene company.


Related Headlines